Loading cancer entity…
Loading cancer entity…
Clinical trials
52 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04851119 | Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors | recruiting | Phase 1 / Phase 2 | 147 | Children's Oncology GroupNETWORK | 1 | Aug 25, 2026 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02076906 | MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors | completed | Phase 1 | 7 | AeRang KimOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03802084 | A Study to Evaluate the Safety and Efficacy of Vactosertib and Imatinib in Patients With Advanced Desmoid Tumor | completed | Phase 1 / Phase 2 | 24 | Hyo Song KimOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT01265030 | A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis | completed | Phase 1 / Phase 2 | 9 | MaineHealthOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT03459469 | Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059 | completed | Phase 1 | 24 | Iterion TherapeuticsINDUSTRY | 2 | Mar 1, 2023 | clinicaltrials |
| NCT00287846 | Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis | completed | Phase 1 / Phase 2 | 40 | UNICANCEROTHER | 1 | Aug 30, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Aug 25, 2026source: clinicaltrials